本帖最后由 老马 于 2012-1-13 21:20 编辑 ' ]) m+ p6 H) z( \2 c
5 q* F: r, D: @+ ^/ o
爱必妥和阿瓦斯丁的比较. e5 ^+ g# |) e7 K
( p9 l8 A' _$ K# b6 G4 Y. F
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 |! S) K& F; I$ S1 i& B
# N$ a/ R4 R) O9 a; I: v+ p+ T$ I
% d4 S7 }5 r& B
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 c. p0 G9 z7 L
==================================================4 o; t5 [) W4 p( B8 ?* B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* N! A+ V8 ?7 Y9 hPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 M+ @1 n2 t4 ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" C0 r8 G: O9 \. p0 a9 l; E
|
显身卡
